Harrow, Inc. HROW
32.16 USD +2.64 (+8.94%)
Regular-session close
32.16 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
29.20 Day range 32.52
26.04 52-week range 54.80
- YTD
- -34.37%
- 1 year
- -19.05%
News
seekingalpha.com Harrow: Strong Revenue Growth And Operating Leverage Ahead Harrow Inc. is positioned to achieve its ambitious $350MM 2026 revenue target after strong Q3 execution. VEVYE and IHEEZO delivered robust sequential growth, with VEVYE up 35% and IHEEZO up 62%…
defenseworld.net 66,773 Shares of Harrow, Inc. $HROW Bought by Drive Wealth Management LLC Drive Wealth Management LLC acquired a new position in Harrow, Inc. (NASDAQ: HROW) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund acquired…
globenewswire.com Harrow to Participate in Two Investor Conferences in November NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will…
seekingalpha.com Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the…
marketbeat.com Harrow Q3 Earnings Call Highlights Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated…
benzinga.com AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but AAON surged 23% on strong earnings and raised guidance. ZipRecruiter, Securitize and Senseonics led other gainers.
benzinga.com Harrow Q3 2026 Earnings Call Transcript Harrow (NASDAQ:HROW) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
zacks.com Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Harrow (HROW) Q3 Earnings Lag Estimates Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $349.747M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $349.747 million estimate.
benzinga.com Harrow Q3 EPS $0.25 Beats $0.22 Estimate, Sales $99.297M Beat $98.501M Estimate Harrow (NASDAQ:HROW) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.22 by 13.64 percent. This is a 24.24 percent decrease over earnings of $0.33 per…
globenewswire.com Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and…
zacks.com Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy? Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease…
globenewswire.com Harrow Launches HarrowRx Platform NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a…
seekingalpha.com Harrow's Top Two Drugs Alone Can Justify Its Current Valuation Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large,…
globenewswire.com Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its…
zacks.com Do Options Traders Know Something About Harrow Stock We Don't? Investors need to pay close attention to HROW stock based on the movements in the options market lately.
defenseworld.net Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They…
globenewswire.com Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for…
defenseworld.net Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One…
globenewswire.com Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific…
defenseworld.net Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were…
defenseworld.net Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN) Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
